Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective The clozapine/N-desmethylclozapine (NDMC) ratio is proposed to be used as a predictor of cognitive performance in clozapine-treated patients, as its principal metabolite, NDMC, has an opposite action with clozapine on the cholinergic system. The aim of this study is to determine whether clozapine has influence on cognitive performance in accordance with changes in the clozapine/NDMC in patients with schizophrenia.Methods The data of fifteen patients with schizophrenia, who had initial and follow-up assessments after starting clozapine treatment, were retrospectively collected. The assessments included clinical scale, cognitive battery, and pharmacological data including plasma concentrations of clozapine and NDMC. The data were analyzed with Pearson correlation and stepwise multiple regression analyses.Results ΔAttention/vigilance, Δsocial cognition, and Δcomposite score had a significant correlation with Δclozapine/NDMC ratio, while ΔWorking memory had correlation with Δclozapine concentration and ΔNDMC concentration, and Δsocial cognition had association with Δclozapine concentration. Multiple regression analysis showed that Δattention/vigilance had negative association with Δclozapine/NDMC ratio, Δworking memory had negative relation with Δclozapine concentration, and that Δsocial cognition had negative association with Δclozapine concentration.Conclusion This finding implicates that lowering the clozapine/NDMC ratio could enhance cognition in patients with schizophrenia treated with clozapine.
Abstract
Objective The clozapine/N-desmethylclozapine (NDMC) ratio is proposed to be used as a predictor of cognitive performance in clozapine-treated patients, as its principal metabolite, NDMC, has an opposite action with clozapine on the cholinergic system. The aim of this study is to determine whether clozapine has influence on cognitive performance in accordance with changes in the clozapine/NDMC in patients with schizophrenia.Methods The data of fifteen patients with schizophrenia, who had initial and follow-up assessments after starting clozapine treatment, were retrospectively collected. The assessments included clinical scale, cognitive battery, and pharmacological data including plasma concentrations of clozapine and NDMC. The data were analyzed with Pearson correlation and stepwise multiple regression analyses.Results ΔAttention/vigilance, Δsocial cognition, and Δcomposite score had a significant correlation with Δclozapine/NDMC ratio, while ΔWorking memory had correlation with Δclozapine concentration and ΔNDMC concentration, and Δsocial cognition had association with Δclozapine concentration. Multiple regression analysis showed that Δattention/vigilance had negative association with Δclozapine/NDMC ratio, Δworking memory had negative relation with Δclozapine concentration, and that Δsocial cognition had negative association with Δclozapine concentration.Conclusion This finding implicates that lowering the clozapine/NDMC ratio could enhance cognition in patients with schizophrenia treated with clozapine.
참고문헌 (38)
- Owen MJ, "Schizophrenia", Lancet, 388, pp.86~97 (2016)
- Joyce EM, "Cognitive heterogeneity in schizophrenia", Curr Opin Psychiatry, 20, pp.268~272 (2007)
- Danion JM, "Functional mechanisms of episodic memory impairment in schizophrenia", Can J Psychiatry, 52, pp.693~701 (2007)
- Galderisi S, "Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives", Schizophr Res, 175, pp.154~160 (2016)
- Citrome L, "Unmet needs in the treatment of schizophrenia : new targets to help different symptom domains", J Clin Psychiatry, 75(Suppl 1), pp.21~26 (2014)
- Nielsen RE, "Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials", Acta Psychiatr Scand, 131, pp.185~196 (2015)
- Davis JM, "A meta-analysis of the efficacy of secondgeneration antipsychotics", Arch Gen Psychiatry, 60, pp.553~564 (2003)
- Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
- Shirazi-Southall S, "Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat", Neuropsychopharmacology, 26, pp.583~594 (2002)
- Nucifora FC Jr, "Clozapine as a Model for Antipsychotic Development", Neurotherapeutics, 14, pp.750~761 (2017)
- Chakos M, "Effectiveness of second-generation antipsychotics in patients with treatmentresistant schizophrenia : a review and meta-analysis of randomized trials", Am J Psychiatry, 158, pp.518~526 (2001)
- Buchanan RW, "The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance", Biol Psychiatry, 36, pp.717~725 (1994)
- Lameh J, "Pharmacology of N-desmethylclozapine", Pharmacol Ther, 115, pp.223~231 (2007)
- Weiner DM, "The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine", Psychopharmacology(Berl), 177, pp.207~216 (2004)
- Snyder S, "Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects", Arch Gen Psychiatry, 31, pp.58~61 (1974)
- Chew ML, "Anticholinergic activity of 107 medications commonly used by older adults", J Am Geriatr Soc, 56, pp.1333~1341 (2008)
- Davies MA, "The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions?", Psychopharmacology (Berl), 178, pp.451~460 (2005)
- Sur C, "N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity", Proc Natl Acad Sci U S A, 100, pp.13674~13679 (2003)
- Bondesson U, "Determination of clozapine and its Ndemethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection", Psychopharmacology(Berl), 95, pp.472~475 (1988)
- Rajji TK, "Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine", Am J Psychiatry, 172, pp.579~585 (2015)
- McArdle PA, "An investigation into the relationship between clozapine treatment and cognitive performance in patients with treatment resistant schizophrenia", Schizophr Res, 206, pp.450~451 (2019)
- Molins C, "Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients", Psychiatry Res, 258, pp.153~157 (2017)
- Rajji TK, "Clozapine and global cognition in schizophrenia", J Clin Psychopharmacol, 30, pp.431~436 (2010)
- Dal Santo F, "Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition : a mediation model", Eur Neuropsychopharmacol, 33, pp.158~163 (2020)
- Aravagiri M, "Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography", electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients, 2001, pp.26, 301~311
- Kay SR, "Reliability and validity of the positive and negative syndrome scale for schizophrenics", Psychiatry Res, 23, pp.99~110 (1988)
- Kern RS, "The MCCB impairment profile for schizophrenia outpatients : results from the MATRICS psychometric and standardization study", Schizophr Res, 126, pp.124~131 (2011)
- Georgiades A, "Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients", Schizophr Res, 190, pp.172~179 (2017)
- Nuechterlein KH, "The MATRICS Consensus Cognitive Battery, part 1 : test selection, reliability, and validity", Am J Psychiatry, 165, pp.203~213 (2008)
- Hasselmo ME, "Modes and models of forebrain cholinergic neuromodulation of cognition", Neuropsychopharmacology, 36, pp.52~73 (2011)
- Couchman L, "Plasma clozapine, norclozapine, and the clozapine : norclozapine ratio in relation to prescribed dose and other factors : data from a therapeutic drug monitoring service, 1993-2007", Ther Drug Monit, 32, pp.438~447 (2010)
- Chetty M, "CYP-mediated clozapine interactions: how predictable are they?", Curr Drug Metab, 8, pp.307~313 (2007)
- Urichuk L, "Metabolism of atypical antipsychotics : involvement of cytochrome p450 enzymes and relevance for drug-drug interactions", Curr Drug Metab, 9, pp.410~418 (2008)
- Cheng YF, "Clinical pharmacokinetics of clozapine in chronic schizophrenic patients", Eur J Clin Pharmacol, 34, pp.445~449 (1988)
- Schoretsanitis G, "A comprehensive review of the clinical utility of and a combined analysis of the clozapine", norclozapine ratio in therapeutic drug monitoring for adult patients, 2019, pp.12, 603~621
- Rostami-Hodjegan A, "Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations : a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients", J Clin Psychopharmacol, 24, pp.70~78 (2004)
- Jacob A, "Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia", Ther Drug Monit, 31, pp.281~282 (2009)
- Rajkumar AP, "Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia", Int Clin Psychopharmacol, 28, pp.50~56 (2013)